DIA Conference Explores the Status of Clinical Trial Registries Worldwide

BASEL, Switzerland--(BUSINESS WIRE)-- DIA in Europe will host the Clinical Trial Registries Conference from May 23-24 in Basel, Switzerland.

This two-day conference will discuss the status of clinical trial registries worldwide and provide insight from the authorities that operate them. Participants will also hear case studies of real-life implementations from industry and academic institutions. Sessions include:

  • Clinical Trial Registries - Overview of Current Situation Worldwide: EU, US and WHO
  • Overview of National, Company and Emerging Registries
  • What Purpose Do Registries Serve? How Do We Measure Their Success?
  • Implementation of Registries in Practice and Technical Implementation
  • Impact of the Clinical Trial Disclosure on the Planning and Conduct of Clinical Trials
  • Publication of Results
  • What Is Beyond Clinical Trials Transparency?

A decade after the launch of the ClinicalTrials.gov database and, more recently, the EU Clinical Trials Register, an increasing number of questions have arisen, including:

  • How can sponsors ensure the consistency and traceability of all the information submitted to these various repositories?
  • How do they organise their processes to deliver the required information in time with limited resources?

“Many still question the purpose of multiple registries and even argue that the original purpose of facilitating patients' access to clinical trials has not been met, while other suggest that industry and investors use the databases as competitive intelligence tools,” says Programme Chair Pierre-Yves Lastic, Senior Director, Data Privacy & Healthcare Interoperability Standards, sanofi-aventis, France. “This conference will convene a distinguished panel of speakers from academia, patients organisations and the pharmaceutical industry to explore the validity of these issues.”

Register for the Clinical Trial Registries Conference.

ABOUT DIA

DIA is a neutral, global, professional, member-driven association of nearly 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies, and services to improve health and well being worldwide. Headquarters are in Horsham, PA, USA, with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China. For more information visit: www.diahome.org.



CONTACT:

DIA Europe
Talana Bertschi, +41 61 225 51 49
[email protected]

KEYWORDS:   Europe  Switzerland

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Pharmaceutical  Communications  Public Relations/Investor Relations  General Health

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.